Beam Therapeutics (BEAM) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
17 Apr, 2026Voting matters and shareholder proposals
Election of three Class III director nominees for three-year terms ending at the 2029 annual meeting.
Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Advisory approval of named executive officer compensation (say-on-pay).
Proxies may vote on other business arising at the meeting or any adjournment.
Board of directors and corporate governance
Board recommends voting for all three director nominees: John Evans, John Maraganore, Ph.D., and Christi Shaw.
Directors to serve three-year terms if elected, expiring at the 2029 annual meeting.
Executive compensation and say-on-pay
Advisory vote to approve compensation of named executive officers is included as a voting item.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Beam Therapeutics
- Single-dose BEAM-302 at 60 mg delivers durable, functional AAT restoration and strong safety in AATD.BEAM
Study result26 Apr 2026 - Director elections, auditor ratification, and executive pay are up for shareholder approval.BEAM
Proxy filing17 Apr 2026 - BEAM-304 for PKU, $500M financing, and strong Q4 net income drive pipeline and cash runway into 2029.BEAM
Q4 202524 Feb 2026 - Base editing platform delivers robust clinical results and pipeline growth, with key 2025 milestones ahead.BEAM
H.C. Wainwright 27th Annual Global Investment Conference3 Feb 2026 - Pivotal sickle cell trial advances and first AAT patient dosing set for this month in the UK.BEAM
Jefferies 2024 Global Healthcare Conference1 Feb 2026 - Q3 net loss $96.7M; $925.8M cash supports pipeline milestones and runway into 2027.BEAM
Q3 202416 Jan 2026 - Clinical and financial milestones drive pivotal launches and pipeline expansion in 2026.BEAM
44th Annual J.P. Morgan Healthcare Conference14 Jan 2026 - Base editing platform delivers promising clinical results and pipeline advances in gene editing.BEAM
Jefferies London Healthcare Conference 202413 Jan 2026 - BEAM-101 delivers robust efficacy in sickle cell; ESCAPE and pipeline advance toward 2025 data.BEAM
Status Update11 Jan 2026